FDA approves Retevmo for lung cancer subset

The FDA granted regular approval to selpercatinib for treatment of certain patients with non-small cell lung cancer (NSCLC). The indication applies to use of selpercatinib (Retevmo, Eli Lilly) by adults with locally advanced or metastatic RET fusion-positive NSCLC as

|
September 22, 2022
|
1 2 3 24